PEP-Therapy and Institut Curie announce first patients dosed in Phase I clinical trial of PEP-010 for the treatment of advanced solid tumors

PARIS, Oct. 5, 2021 /PRNewswire/ -- PEP-Therapy, a clinical-stage biotechnology company developing cell penetrating peptides as targeted therapies in oncology, and Institut Curie, France's leading cancer center, today announce that the first patients have been dosed in a Phase Ia/b...

from PR Newswire: https://ift.tt/3oxN1bL